Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study

J.M. Fernández-Armenteros,1,2,* X. Gómez-Arbonés,1,3 M. Buti-Soler,4,5 A. Betriu-Bars,1,6
V. Sanmartin-Novell,2 M. Ortega-Bravo,7 M. Martínez-Alonso,1 E. Gari,1 M. Portero-Otín,1
L. Santamaria-Babi,8 J.M. Casanova-Seuma1,2,3
1Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain
2Dermatology Department, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain
3Department of Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain
4Unitat de Suport a la Recerca Lleida, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Spain
5Institut Català de la Salut, Lleida, Spain
6Nephrology Department, Unitat de Detecció i Tractament de les malalties aterotrombòtiques (UDETMA), Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain
7CAP Cappont, Lleida, Spain
8Translational Immunology, University of Barcelona, Barcelona, Spain
*Correspondence: J.M. Fernández-Armenteros. E-mail: josepmamela27@gmail.com

Abstract
Background  Psoriasis is a very prevalent systemic chronic inflammatory disease. Major cardiovascular events are the main cause of mortality in these patients which suggests an association between psoriasis and traditional cardiovascular risk factors.

Objective  To identify classic cardiovascular risk factors and metabolic syndrome (MS) in patients with psoriasis, their possible association with its severity and compare it with the non-psoriatic population.

Methods  This is an observational and cross-sectional population study in Lleida (Spain) from a joint hospital/primary care database.

Results  The database comprised 398 701 individuals. There were 6868 cases registered as psoriasis (1.7%), and 499 of them (7.3%) were classified as moderate–severe psoriasis. Patients with psoriasis had a higher prevalence of traditional cardiovascular risk factors than non-psoriatic population: diabetes mellitus 2 (13.9% vs 7.4%, OR 2.01), dyslipidaemia (28.8% vs 17.4%, OR 1.92), arterial hypertension (31.2% vs 19.0%, OR 1.93), obesity (33.7% vs 28.1%, OR 1.30), altered fasting basal glycaemia (21.4% vs 15.1%, OR 1.54), low cholesterol HDL (38.1% vs 32.3%, OR 1.29), hypertriglyceridaemia (45.7% vs 35.2%, OR 1.55) and high waist circumference (75.7% vs 72.3%, OR 1.19). MS was more prevalent in psoriatic patients (28.3% vs 15.1%, OR 2.21), and cardiovascular risk factors were similar between psoriasis severity groups. Psoriatic patients had a higher prevalence of ischaemic heart disease (3.3% vs 1.8%, OR 1.87) and vascular cerebral accidents (1.8% vs 1.2%, OR 1.55). A model for MS showed a significant nonlinear relationship with age and sex and significant differences between patients with and without psoriasis.

Conclusion  We found statistically significant differences in relation to the prevalence of cardiovascular risk factors, MS and major cardiovascular events in psoriatic patients. However, differences were not seen between psoriasis severity groups. Our work reinforces the need for a multidisciplinary approach and close monitoring of cardiovascular risk factors in these patients to prevent a cardiovascular event.

Conflict of interests
The authors have no conflict of interests to disclose.

Funding
No funding sources need to be credited.
Psoriasis and cardiovascular risk factors

Introduction
Psoriasis is a very prevalent chronic inflammatory disease. In recent years, this disease has been associated with several comorbidities, and nowadays, it is considered a systemic inflammatory disease. Major cardiovascular events are the main cause of mortality in patients with psoriasis, which suggests that there are associations between psoriasis and traditional cardiovascular risk factors. It has been described a link between psoriasis and obesity, dyslipidaemia, diabetes mellitus (DM2) and hypertension. This association is probably due to genetic, environmental and immunological factors, such as Th1 and Th17 pathway activation, proinflammatory cytokines and increased oxidative stress. All these factors induce endothelial dysfunction, which promotes leucocyte adhesion and favours a prothrombotic state.

Regarding the metabolic syndrome (MS), a systemic inflammatory and prothrombotic disease, a recent meta-analysis confirmed a strong association between this syndrome and psoriasis (OR 2.14; 95% CI 1.84–2.48). All this would lead to a higher cardiovascular disease mortality in psoriasis (OR 1.37: 95% CI 1.17–1.60), myocardial infarction (OR 3.04, 95% CI, 0.65–14.35) and stroke (OR 1.59, 95% CI, 1.34–1.89). This risk seems to be higher in patients with severe psoriasis.

As not all studies confirm a link between psoriasis and cardiovascular risk factors, this topic is still controversial. Furthermore, most studies were conducted in the United States, northern Europe and Asia, regions where culture, diet and other risk factors for metabolic and cardiovascular disease are different from the Mediterranean region. We decided to conduct a population study in Lleida, Catalonia, in the north-east of Spain. Conclusive results of an association between cardiovascular risk factors and psoriasis would reinforce the need for a multidisciplinary assessment of these patients, not only by the dermatologist, as well as a modification of their lifestyle and a strict cardiovascular risk management.

Objectives
1. To obtain the prevalence of MS and classical risk factors: hyperglycaemia and DM2, hypercholesterolaemia, decreased cholesterol-HDL, hypertriglyceridaemia, increased abdominal perimeter and arterial hypertension in patients with psoriasis (subdivided into severity groups) and control population.
2. To calculate the percentage of major cardiovascular events (acute myocardial infarction and stroke) in the psoriasis group and compare it to the non-psoriatic group.
3. To analyse the probability of MS depending on sex, age, psoriasis diagnosis and severity.

Materials and methods
This is an observational and cross-sectional population study on electronic records of residents in the province of Lleida, Catalonia, Spain. Databases from Primary Care and the Dermatology Department of the Hospital Universitario Arnau de Vilanova de Lleida (the only Dermatology Department in the province) were collected in June 2016, provided by the ‘Unitat de Recerca de l’Institut Català de Salut’ of Lleida (UR-ICS-Lleida). From the resulting database, duplications were eliminated and the records with the diagnosis of cutaneous psoriasis (L40) were selected. The UR-ICS-Lleida built the final database, erasing identifiers. The cases were assigned an internal code the UR-ICS-Lleida knows and that allowed to review or to verify the information of each register if it were necessary. This dissociated database (anonymous for researchers) only contained variables relevant to the study. These variables included sex, age, height, weight (to obtain the body mass index), diagnosis of psoriasis, drugs used for the treatment of psoriasis, cardiovascular risk factors such as DM2 (E11), hypertension (I10), hypercholesterolaemia (E78.0), decreased HDL (E78.6), hypertriglyceridaemia (E78.1), major cardiovascular disease: acute myocardial infarct (I21, I22) and stroke (I63).

Table 1 Diagnostic criteria of some classic cardiovascular risk factors

| **Diabetes mellitus** | • Fasting plasma glucose ≥126 mg/dL
| (any of the following) | • Random plasma glucose ≥200 mg/dL in a patient with classical symptoms of hyperglycaemia (polyuria, polydipsia, polyphagia and weight loss)
| | • HbA1c level of 6.5% or higher
| | • Registered diagnosis of diabetes mellitus
| **Arterial hypertension** | • Elevated blood pressure (>140/90 mmHg) on at least 3 separate occasions
| (any of the following) | • Registered diagnosis of hypertension
| **Dyslipidaemia** | • Hypercholesterolaemia (total cholesterol ≥250 mg/dL or registered diagnosis of hypercholesterolaemia) ± hypertriglyceridaemia (plasma triglycerides ≥150 mg/dL or registered diagnosis of hypertriglyceridaemia)
| | • 2-h plasma glucose level ≥200 mg/dL during a 75-g oral glucose tolerance test
| **Elevated Body Mass Index** | • 25–29.9 kg/m²: overweight
| | • ≥30 m²: obesity

Table extracted from: *Chamberlain JJ, 2016; Chobanian AV, 2003; Diaz A, 2014; National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), 2000.*
Diagnostic criteria of classical cardiovascular risk factors and MS are summarized in Tables 1 and 2, and the lack of data in a MS criterion was considered a non-pathological value.

As BSA and PASI are not usually registered in Primary Care, we defined moderate–severe psoriasis according to the treatment prescribed. This method has been used previously by some authors.13 Each subject was registered as a moderate–severe psoriatic patient when he or she had been treated with narrowband UVB (NB-UVB), psoralen and ultraviolet A (PUVA), traditional systemic drugs (acitretin, methotrexate or cyclosporine) or biological therapy (infliximab, etanercept, adalimumab, ustekinumab, secukinumab or ixekizumab), defining the rest as mild psoriasis. The study was approved by the ‘Hospital Arnau de Vilanova de Lleida ethics committee’ (CEIC-1655).

The anonymized database was captured and analysed with SPSS v24.0 software (IBM Corporation, Armonk, NY, USA). Comparisons of proportions and ranges of variables between different groups were performed by chi-square, Student’s t-test or one-way ANOVA as appropriate. The calculated odds ratios compared the occurrence of each cardiovascular risk factor or major cardiovascular event in the presence or absence of psoriasis. The selected P value for considering differences as statistically significant in all analyses was P < 0.05.

A model to assess the association between metabolic syndrome and having a psoriasis diagnosis once adjusted by the relationship with age and sex was modelled by multivariable logistic regression model. Nonlinear association with age was allowed using natural cubic splines. The existence of first- and second-order interactions was also assessed. Statistical contribution of variables or interaction terms was assessed by likelihood ratio test. Model calibration and discrimination were assessed by Hosmer–Lemeshow test and AUC estimation. A graphic was drawn to facilitate the interpretation of the resulting model (Fig. 1). A second model was fitted with the psoriasis diagnosis graded in three levels: none, mild or moderate/severe (Fig. 2). A significance level of 0.05 and the software R14 were used.14

### Results

The joint hospital/primary care database collected a total of 398,701 individuals. The mean age was 42.34 years, and the percentage of males was 50.7%. We obtained 6868 patients (1.7% of the population) catalogued as psoriatic (55.3% were males). Male prevalence of psoriasis was 1.9% and in women was 1.6%. There were 499 patients whose psoriasis was classified as moderate–severe (7.27% of patients with psoriasis).

Firstly, prevalence and odds ratio of classical cardiovascular factors were calculated comparing psoriatic and non-psoriatic population (Table 3a). The psoriasis group had a higher prevalence of DM2 (13.9%; OR 2.01, 95% CI: 1.87–2.15, P < 0.001); dyslipidaemia (28.8%; OR 1.92, 95% CI: 1.82–2.03, P < 0.001); arterial hypertension (31.2%; OR 1.93, 95% CI: 1.83–2.03, P < 0.001); and obesity (33.7%; OR 1.30, 95% CI: 1.22–1.39, P < 0.001). In this first statistical evaluation, the lack of any pathological data was considered as a non-pathological individual according to each criterion.

The occurrence of major cardiovascular events was studied in patients with psoriasis and non-psoriatic population (Table 3b). The history of ischaemic heart disease was evidenced in 229 patients with psoriasis (3.3%) (OR 1.87, 95% CI: 1.63–2.13, P < 0.001). In relation to vascular-cerebral disease, the proportion was higher in patients with psoriasis (1.8%) than in the non-psoriatic population (OR 1.55, 95% CI: 1.29–1.86, P < 0.001).

To demonstrate the accuracy of these data, a further analysis focusing on MS was performed. This evaluation only included individuals who had at least one recorded data (whether pathological or not), and not all the individuals from the psoriasis and non-psoriatic groups. MS was more prevalent in the psoriasis group (28.3% vs 15.1%), with an OR of 2.21 (95% CI: 2.10–2.33, P < 0.001). All of the MS criteria were analysed individually (Table 3c) and were also more prevalent in the psoriasis group. Focusing on major cardiovascular events in patients with MS, a 7.4% of these patients presented an acute coronary event and 4.3% had suffered a vascular-cerebral disease.

Moreover, the prevalence of MS, other classic cardiovascular risk factors and cardiovascular major events was studied depending on psoriasis severity. In this case, the proportion of these diagnoses was not higher in the moderate–severe psoriasis group, and only a tendency was seen between a more severe disease and prevalence of metabolic syndrome (Table 4).

The model for metabolic syndrome included the variables sex, age and psoriasis diagnosis. The resulting model showed a significant nonlinear relationship with age and only one significant interaction, the one between sex and the nonlinear effect of age, modelled by natural cubic splines of 3 degrees of freedom.

---

**Table 2 Diagnostic criteria of metabolic syndrome**

| Metabolic syndrome* (at least 3 criteria†): |   |
|------------------------------------------|--|
| • Fasting glucose ≥100 mg/dL (or receiving drug therapy for hyperglycaemia) |   |
| • Blood pressure ≥130/85 mmHg (or receiving drug therapy for hypertension) |   |
| • Triglycerides ≥150 mg/dL (or receiving drug therapy for hypertriglyceridaemia) |   |
| • HDL <40 mg/dL in men or <50 mg/dL in women (or receiving drug therapy for reduced HDL) |   |
| • Waist circumference ≥102 cm in men or ≥88 cm in women |   |

*National Heart, Lung and Blood Institute (NHLBI) and American Heart Association (AHA), 2005.
†The lack of data in a criterion was considered a non-pathological value.
significant interaction was obtained with psoriasis diagnosis. Thus, the nonlinear association between age and the metabolic syndrome was significantly different for men and women, as shown in Fig. 1. This figure shows the estimated probability of metabolic syndrome in association with age for the groups defined by the combinations of sex and psoriasis diagnosis. Both models, the one for psoriasis diagnosis and the other for psoriasis grade, showed good calibration (predicted and observed probabilities were very close to each other) and good discrimination, both with a 0.855 area under the curve.

Figure 1 shows the predicted probability of metabolic syndrome depending on age, sex and psoriasis diagnosis. A nonlinear association with age that is dependent on sex was identified. Significant differences in the estimated probability of metabolic syndrome between patients with and without psoriasis already appear around the age of 30 years, showing higher probabilities in patients with psoriasis, men or women. Besides, men with psoriasis diagnosis showed a significantly higher probability of metabolic syndrome than women with psoriasis till the age of almost 70 years, where estimated probabilities became very similar. Women older than around 75 years old showed increasing estimated probabilities of metabolic syndrome, in contrast with men, who showed an inflexion point around that age and a decreasing estimated trend from that age. This inflexion point is common to non-psoriasis patients. The OR of metabolic syndrome for psoriasis vs. non-psoriasis patients (the only variable in the model showing an additive effect) was 1.60, with 95% CI = [1.51, 1.70]. Thus, for example, if we try to estimate the probability of metabolic syndrome for a 52-year-old patient (the median age of patients with psoriasis), the expected probability of metabolic syndrome is 0.16 if a woman without psoriasis, 0.20 if it a man without psoriasis, 0.23 if a women with psoriasis and 0.29 if a man with psoriasis. These differences are increased for older ages, and for a 66-year-old patient, these estimates are 0.36, 0.39, 0.47 and 0.51, respectively.

Figure 2 shows the predicted probability of metabolic syndrome depending on age, sex and psoriasis grade of severity. The psoriasis group was divided into mild or moderate/severe disease. Although estimated probabilities are higher for the moderate/severe psoriasis group in both, men and women, their confidence intervals are overlapped. This overlap is consequence of the wide confidence interval obtained from the small number of patients with moderate/severe psoriasis. The OR of metabolic syndrome of mild psoriasis vs. non-psoriasis patients and for moderate/severe psoriasis vs. non-psoriasis (the only variable in the model showing an additive effect)
was 1.58, with 95% CI = [1.48, 1.68] and 1.94 with 95% CI = [1.56, 2.39], respectively. No significant differences were observed, independently of patient age, between the probabilities of metabolic syndrome for mild versus moderate/severe psoriasis patients.

**Discussion**

In our study, statistically significant differences were found in relation to the prevalence of cardiovascular risk factors in patients with psoriasis, presenting a higher frequency of DM2, dyslipidaemia, hypertension and obesity. In this first statistical evaluation, the lack of any pathological data was considered as a non-pathological individual according to each criterion. We know individuals with these factors have a higher rate of cardiovascular events such as a heart attack or stroke, which are the main cause of death in patients with psoriasis, and this association has already been objectified in multiple studies (Table 5). As it seems to be an association between DM2, dyslipidaemia, hypertension, obesity and psoriasis, some authors suggest that there is an early common pathogenesis (involving several adipokines and inflammatory cytokines) both in the cutaneous disease and in the other risk factors.\(^{15}\)

In addition, the proportion of MS in the population with psoriasis was also higher than in the general population and we designed a model which predicted the probability of MS that showed a significant nonlinear relationship with age, sex and psoriasis.

Our results were slightly smaller than other similar published studies (Table 6), although some other authors did not find this association (25.81% vs 21.02%, \(P > 0.05\)).\(^{16}\) Our data were obtained from a joint database between hospital and primary care and include one of the largest series ever published related to psoriasis and cardiovascular risk factors in Mediterranean regions, a factor that is increasingly involved in cardiovascular morbidity and mortality. We believe this makes the sample of individuals more representative of the population, and the fact that this evaluation only included individuals who had at least one recorded data, whether pathological or not, may be more reliable. It should be considered that carrying out prevalence studies in different populations with a similar methodology would help us to assess which factors influence in the variability of the results obtained.

Analogously, we obtained a higher prevalence of each MS diagnostic criteria (altered fasting glycaemia, altered blood
Table 3 (a) Prevalence of cardiovascular risk factors, metabolic syndrome and its criteria in psoriasis and general population. (b) Prevalence of major cardiovascular events in psoriasis and general population. (c) Prevalence of metabolic syndrome and its criteria in psoriasis and general population

| (a) | Psoriasis | Non-psoriasis | OR (CI 95%) |
|-----|-----------|---------------|-------------|
| Diabetes mellitus 2 | 952 (13.9%) | 29 171 (7.4%) | 2.01 (1.87–2.15, P < 0.001) |
| Dyslipidaemia | 1979 (28.8%) | 68 201 (17.4%) | 1.92 (1.82–2.03, P < 0.001) |
| Arterial hypertension | 2140 (31.2%) | 74 489 (19.0%) | 1.93 (1.83–2.03, P < 0.001) |
| Obesity | 1497 (33.7%) | 47 184 (28.1%) | 1.30 (1.22–1.39, P < 0.001) |

| (b) | Psoriasis | Non-psoriasis | OR (CI 95%) |
|-----|-----------|---------------|-------------|
| Ischaemic cardiomyopathy | 229 (3.3%) | 7116 (1.8%) | 1.87 (1.63–2.13, P < 0.001) |
| Cerebrovascular disease | 122 (1.8%) | 4520 (1.2%) | 1.55 (1.29–1.86, P < 0.001) |
| Total | 6868 | 391 833 |  |

| (c) | Psoriasis | Non-psoriasis | OR (CI 95%) |
|-----|-----------|---------------|-------------|
| Fasting glucose ≥100 mg/dL | 1333/6222 (21.4%) | 42 417/281 436 (15.1%) | 1.54 (1.45–1.63, P < 0.001) |
| HDL <40 mg/dL in men or <50 mg/dL in women | 2067/5429 (38.1%) | 71 574/221 678 (32.3%) | 1.29 (1.22–1.36, P < 0.001) |
| Triglycerides ≥150 mg/dL | 2754/6021 (45.7%) | 92 140/261 647 (35.2%) | 1.55 (1.47–1.63, P < 0.001) |
| Blood pressure ≥130/85 mmHg | 3174/6356 (49.9%) | 111 860/315 177 (35.5%) | 1.81 (1.73–1.91, P < 0.001) |
| Waist circumference ≥102 cm in men or ≥88 cm in women | 1787/2362 (75.7%) | 58 311/80 613 (72.3%) | 1.19 (1.08–1.31, P < 0.001) |
| Metabolic syndrome | 1941/6868 (28.3%) | 59 280/391 833 (15.1%) | 2.21 (2.10–2.33, P < 0.001) |

The calculated odds ratios compare the occurrence of each cardiovascular risk factor in the presence or absence of psoriasis.

*Based on National Heart, Lung and Blood Institute (NHLBI) and American Heart Association (AHA), 2005.

Table 4 Prevalence of cardiovascular risk factors, metabolic syndrome and major cardiovascular events according to severity of psoriasis

|                | Mild psoriasis | Moderate–severe psoriasis | OR (CI 95%) |
|----------------|----------------|--------------------------|-------------|
| Diabetes mellitus | 885 (13.9%) | 67 (13.4%) | 0.96 (0.74–1.26, P = 0.771) |
| Dyslipidaemia | 1845 (29%) | 134 (26.9%) | 0.90 (0.73–1.11, P = 0.315) |
| Arterial hypertension | 2008 (31.5%) | 132 (26.5%) | 0.78 (0.64–0.96, P = 0.018) |
| Metabolic syndrome | 1784 (28%) | 157 (31.5%) | 1.18 (0.97–1.44, P = 0.099) |
| Ischaemic cardiomyopathy | 207 (3.3%) | 22 (4.4%) | 1.37 (0.88–2.15, P = 0.165) |
| Cerebrovascular accident | 116 (1.8%) | 6 (1.2%) | 0.66 (0.29–1.50, P = 0.314) |
| Total | 6369 | 499 |  |

pressure, low HDL, hypertriglyceridaemia and altered waist circumference) in patients with psoriasis, which reinforces the close association and burden of cardiovascular morbidity in this cutaneous disease.

It would be interesting to investigate in future studies whether there is also a correlation between these parameters and other comorbidities associated with psoriasis such as non-alcoholic fatty liver disease (NAFLD). This entity, which according to some authors is closely linked to obesity and metabolic syndrome, is the most prevalent liver disease, and its incidence is increased in patients with psoriasis.18 Due to the risk of hepatocarcinoma from NAFLD, it would be appropriate to assess whether there is a carcinogenic risk from psoriasis itself or a negative influence of skin lesions on lifestyle.

Moreover and surprisingly, no statistically significant differences were found between a higher severity of psoriasis and a greater association with cardiovascular risk factors, and there was only a tendency between psoriasis severity and MS prevalence (1.18, 95% CI: 0.97–1.44, P = 0.099). Some authors obtained a greater risk of MS in patients with psoriasis than general population (OR 1.91; 95% CI 1.47–2.49).19 These authors also classified psoriasis severity depending on their treatment–moderate–severe psoriasis prevalence calculated is similar, so we think that geographical or cultural factors could explain these differences. Curcò et al.20 could neither find an association, even though a link between psoriasis severity and diabetes mellitus was described.

Focusing on the risk of major cardiovascular risk events in psoriasis, Parisi et al.21 did not find this link in a Manchester cohort study (2.59% vs 2.30%), as well as in a recent meta-analysis which neither found an association with cerebrovascular disease (OR 1.1; CI 0.9–1.3). On the contrary, an increased risk of ischaemic heart disease in patients with psoriasis (OR 1.5; 95% CI 1.2–1.9) was obtained.22 Our data corroborate the increased risk of
Table 5 Prevalence of cardiovascular risk factors and major cardiovascular events in psoriasis and general population

| Risk factor/cardiovascular event | Prevalence in psoriasis | Prevalence in non-psoriasis group | OR (IC 95%) | Author |
|----------------------------------|-------------------------|-----------------------------------|-------------|--------|
| Diabetes mellitus                | 952 (13.9%) 15 (11.3%)  | 29 171 (7.4%)                    | 2.01 (1.87–2.15, P < 0.001) | Our results (2018) |
|                                  |                         |                                   | 1.59 (1.38–1.83)            | Jacobi et al. (2013) |
|                                  |                         |                                   | 1.9 (1.5–2.5)               | Armstrong et. al. (2013) |
|                                  |                         |                                   | 1.76 (1.59–1.96)            | Miller et al. (2013) |
| Dyslipidaemia                    | 1979 (28.8%) 68 201 (17.4%) |                                  | 1.92 (1.82–2.03, P < 0.001) | Our results (2018) |
|                                  |                         |                                   | 1.04–5.55                  | Ma et al. (2013) |
|                                  |                         |                                   | 1.5 (1.4–1.7)               | Miller et. al. (2013) |
| Decreased HDL                    | 2067 (38.1%) 29.8% 26 (27.37%) | 71 574 (32.3%)                    | 1.29 (1.22–1.36, P < 0.001) | Our results (2018) |
|                                  |                         |                                   | 8.57 (P < 0.001)            | Belinchón et al. (2015) |
|                                  |                         |                                   |                             | Salunke et al. (2017) |
| Hypertriglyceridaemia            | 2754 (45.7%) 34.7% 43 (45.26%) | 92 140 (35.2%)                    | 1.55 (1.47–1.63, P < 0.001) | Our results (2018) |
|                                  |                         |                                   |                             | Belinchón et al. (2015) |
|                                  |                         |                                   |                             | Salunke et al. (2017) |
| Arterial hypertension            | 2140 (31.2%) 52 (39.1%) | 74 489 (19.0%)                    | 1.93 (1.83–2.03, P < 0.001) | Our results (2018) |
|                                  |                         |                                   | 1.8 (1.6–2.0)               | Jacobi et al. (2013) |
|                                  |                         |                                   | 1.58 (1.42–1.76)            | Miller et al. (2013) |
| Obesity                          | 1497 (33.7%) 47 184 (28.1%) |                                  | 1.30 (1.22–1.39, P < 0.001) | Our results (2018) |
|                                  |                         |                                   | 1.8 (1.4–2.2)               | Miller et al. (2013) |
| High waist circumference         | 1787 (75.7%) 58 311 (72.3%) |                                  | 1.19 (1.08–1.31, P < 0.001) | Our results (2018) |
|                                  |                         |                                   |                             | Belinchón et. al. (2015) |
|                                  |                         |                                   |                             | Salunke et al. (2017) |
|                                  |                         |                                   |                             | Miller et al. (2013) |
| Ischaemic cardiomyopathy         | 229 (3.3%) 7116 (1.8%) |                                  | 1.87 (1.63–2.13, P < 0.001) | Our results (2018) |
|                                  |                         |                                   | 1.5 (1.2–1.9)               | Jacobi et al. (2013) |
| Cerebrovascular accident         | 122 (1.8%) 4520 (1.2%) |                                  | 1.55 (1.29–1.86, P < 0.001) | Our results (2018) |
|                                  |                         |                                   | 1.1 (0.9–1.3)               | Miller et al. (2013) |

Table 6 Prevalence and association between psoriasis and metabolic syndrome according to some recent studies

| Author                  | Country          | Patients with psoriasis | Patients with metabolic syndrome in psoriasis group | Patients with metabolic syndrome in control group | Association between metabolic syndrome in patients with psoriasis |
|-------------------------|------------------|-------------------------|----------------------------------------------------|--------------------------------------------------|---------------------------------------------------------------|
| Langan et al. (2012)    | United Kingdom   | 4065                    | 1389 (34.2%)                                       | 10 515 (25.9%)                                    | OR = 1.50 (1.40–1.61)                                          |
| Owczarczyk-Saczonek (2015) | Poland           | 62                      | 16 (25.8%)                                         | 181 (21.02%)                                      | P > 0.05                                                      |
| Albareda et al. (2014)  | Spain            | 102                     | 53 (52.9%)                                         | 35 (34.31%)                                      | P < 0.016                                                     |
| Parodi et al. (2014)    | Spain            | 380                     | 102 (26.84%)                                       | 52 (15.16%)                                      | OR = 1.96 (P < 0.0001)                                         |
| Belinchón et al. (2015) | Spain            | 352                     | 132 (37.5%)                                        | No control group                                 | No control group                                              |
| Danielsen et al. (2015) | Norway           | 1137                    | 33%                                                 | 25%                                              | OR = 1.43                                                     |
| Curcó et al. (2017)     | Spain            | 178                     | 30%                                                 | No control group                                 | No control group                                              |
| Milčić et al. (2017)    | Serbia           | 244                     | 110 (45.1%)                                        | 32 (19.6)                                        | OR = 2.66 (P < 0.001)                                          |
| Our results (2018)      | Spain            | 6868                    | 1941 (28.3%)                                       | 59 280 (15.1%)                                    | OR = 2.21 (2.10–2.33, P < 0.001)                              |

suffering a major cardiovascular event in patients with psoriasis, both ischaemic heart disease (OR 1.87, 95% CI: 1.63–2.13, P < 0.001) and cerebrovascular disease (OR 1.55, 95% CI: 1.29–1.86, P < 0.001). The hypothesis that a chronic inflammatory disease such as psoriasis may have an independent role in the pathogenesis of a cardiovascular event is not unreasonable, and many authors have linked systemic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus or
inflammatory bowel disease with an increased cardiovascular risk. More publications should be performed to elucidate this topic.

Limitations
The main limitations of this study are those inherent in a cross-sectional population study, such as the lack of data from some patients. In addition, as it is a study focused on the MS, smoking was not included. Similarly, medications for cardiovascular risk factors such as antidiabetic or lipid-lowering drugs were not considered, so there could be patients without a coded diagnosis which would be excluded.

Conclusion
Taking into account the data presented above and the review of previous publications regarding the relation between psoriasis, MS and cardiovascular risk factors, we suggest that our work reinforces the need for close monitoring of cardiovascular risk factors in patients with psoriasis which are often only visited by the dermatologist to prevent a major cardiovascular event. Further studies would help us to discern whether psoriasis really acts as an independent factor, and it would also be interesting to assess whether an adequate management of the cutaneous disease would help to control other risk factors or reduce its cardiovascular risk in the long term.

References
1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 205–212.
2. Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol 2017; 76: 377–390.
3. Kumar S, Han J, Li T et al. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 2013; 27: 1293–1298.
4. Ma C, Harskamp CT, Armstrong EI et al. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 2013; 168: 486–495.
5. Armstrong AW, Harskamp CT, Armstrong EI. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 84–91.
6. Armstrong AW, Harskamp CT, Armstrong EI. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2013; 31: 433–442.
7. Correia B, Torres T. Obesity: a key component of psoriasis. Acta Biomed 2015; 86: 121–129.
8. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–1741.
9. Steyers CM 3rd, Miller EF Jr. Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci 2014; 15: 11324–11349.
10. Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS ONE 2017; 12: e0181039.
11. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340–2346.
12. Ogdie A, Troxel AB, Mehta NN, Gelfand JM. Psoriasis and cardiovascular risk: strength in numbers part 3. J Invest Dermatol 2015; 135: 2148–2150.
13. Takeshita J, Gelfand JM, Li P et al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol 2015; 135: 2955–2963.
14. R Core Team (2018). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. URL: https://www.R-project.org/.
15. Katsiki N, Anagnostis P, Athyros VG, Karagiannis A, Mikhailidis DP. Psoriasis and vascular risk: an update. Curr Pharm Des 2014; 20: 6114–6125.
16. Owczarczyk-Saczonek AB, Nowicki RJ. Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. Postepy Dermatol Alergol 2015; 32: 290–295.
17. Scalerà A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol 2014; 20: 9217–9228.
18. Pietrzak D, Pietrzak A, Krasowska D et al. Digestive system in psoriasis: an update. Arch Dermatol Res 2017; 309: 679–693.
19. Snekvik I, Nilsen TIL, Romundstad PK, Suunes M. Psoriasis and cardiovascular disease risk factors. The HUNT Study, Norway. J Eur Acad Dermatol Venereol 2018; 32: 776–782.
20. Curcó N, Barrientos N, Barahona MJ et al. Factors influencing cardiometabolic risk profile in patients with psoriasis. Australas J Dermatol 2018; 59: e93–e98.
21. Parisi R, Rutter MK, Lunt M et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol 2015; 135: 2189–2197.
22. Miller JM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013; 69: 1014–1024.
23. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2: 99–106.
24. Albareda M, Ravella A, Castelló M, Saborit S, Peramiquel L, Vila L. Metabolic syndrome and its components in patients with psoriasis. Springerplus 2014; 3: 612.
25. Belinchón I, Vanaclocha F, De la cueva-dobao P et al. Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. J Dermatol Treat 2015; 26: 318–325.
26. Jacobí A, Kupce C, Behzad M, Herrl M. Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study. Int J Dermatol 2015; 52: 1081–1087.
27. Coto-segura P, Eiris-salvado N, González-lara L et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol 2013; 169: 783–793.
28. Salunke AS, Nagargoje MV, Belgaumkar VA, Tolat SN, Chavan RB. Association of metabolic syndrome in chronic plaque psoriasis patients and their correlation with disease severity, duration and age: a case control study from Western Maharashtra. J Clin Diagn Res 2017; 11: WC06–WC10.
29. Langan SM, Seminara NM, Shin DB et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132: 556–562.
30. Parodi A, Aste N, Calviert C et al. Metabolic syndrome prevalence in psoriasis: a cross-sectional study in the Italian population. Ann J Clin Dermatol 2014; 15: 371–377.
31. Danielsen K, Wilsgaard T, Olsen AO et al. Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences. Br J Dermatol 2015; 172: 419–427.
32. Milkič D, Jankoviš, Vesiš S et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study. An Bras Dermatol 2017; 92: 46–51.